Professor Torben Plesner, MD, Doctor of Medical Science

Professor of Haematology, Department of Haematology, The University of Southern Denmark

Vejle, Denmark
 
Biography:
 
Present position: Consultant of Hematology and Head of Department of Hematology, Section of Internal Medicine, Vejle Hospital and from March 2009: Professor of Hematology, University of Southern Denmark. Founder and leader of the Clinical Research Unit at the Department of Hematology, Vejle Hospital since 2003.
 
Scientific profile: I have published 92 scientific articles that are indexed in PubMed. ISI Web of Science has 84 hits for scientific articles with 2576 citations giving an average of 30 citations per item and a “H-index” of 28.
Thesis accepted by University of Copenhagen July, 1981 in fulfillment of Doctor of Medical Sciences degree. Thesis title: "Immunochemical Studies of Human β2-Microglobulin. A Review of Recent Methodological Progress and Clinical Ap¬plications".
 
Lifeline: Born on 28. February 1947.
Medical Degree: University of Copenhagen. First part: 1968. Second part: 1972.
Certified as clinical chemistry (MD) Specialist in Denmark, 1981.
Certified as internal medicine Specialist in Denmark, 1989.
Certified as hematology Specialist in Denmark, 1990.
1. March 1993 - 30. September 2000: Consultant of Hematology, Herlev Hospital, University Hospital, Copenhagen.
From 1. October 2000: Present position.
 
Clinical research experience:
The Clinical Research Unit at the Department of Hematology, Vejle Hospital has about 20 ongoing trials. I have an official GCP course certificate and personal GCP training per protocol and from investigator meetings as principal investigator or co-investigator. I am a member of the Danish Society for GCP, member of the national board of coordinators of the CRUs of the Hematological Departments in Denmark and member of the Clinical Trial Subcommittee of the European Myeloma Network. I have participated in international conferences focussed on improved quality of Clinical Research. I am a member of Advisory Boards for Genmab and Janssen and Celgene. I am investigator for Genmab, Janssen, Celgene, Bristol Myers Squibb, Novartis, Roche, Nordic Myeloma Study Group, HOVON and the German CLL Study Group. I am recipient of research grants from Janssen, Celgene, Roche and Novartis.
My main focus of research is on multiple myeloma.
 
Session:
 
21st November 2015 (Saturday) 11:00 - 11:30
 
Plenary Section II
The Travel with Daratumumab: From a Phase 1 First-in-Man Trial to the Market